Assoc Prof Ng Kok Pin is a Senior Consultant at the Department of Neurology, National Neuroscience Institute. After graduating from the Yong Loo Lin School of Medicine, National University of Singapore in 2006, he obtained his MRCP(UK) in 2011 and was accredited as a Neurologist by the Ministry of Health Singapore in 2015. In 2016, he obtained his Master of Clinical Investigation (NUS).

Assoc Prof Ng subspecialises in dementia and his research interest is PET imaging in neurocognitive diseases. He completed his 1-year clinical research fellowship at the McGill University Research Centre for Studies in Aging, Montreal, Canada in 2017.

• MCI (NUS), 2015
• MRCP (UK), 2011
• MBBS National University of Singapore, 2006

• Senior Consultant, Department of Neurology, National Neuroscience Institute
• Clinical Lecturer, Yong Loo Lin School of Medicine (NUS)
• Teaching Faculty, NTU Lee Kong Chian Medicine School of Medicine

• NMRC Research Training Fellowship, 2016
• MOH Healthcare Research Scholarship, 2014

• Alzheimer’s dementia
• PET imaging in dementia

• ​Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., et al. 2017. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 88(19), pp.1814-1821.
• Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Therriault, J., Kang, M.S., Shin, M., Guiot, M.C., Guo, Q., Harada, R., Comley, R.A. and Massarweh, G., 2017. Monoamine oxidase B inhibitor, selegiline, reduces 18 F-THK5351 uptake in the human brain. Alzheimer's Research & Therapy, 9(1), p.25.
• Li, X., Ba, M., Ng, K.P., Mathotaarachchi, S., Pascoal, T.A., Rosa-Neto, P., Gauthier, S. and Alzheimer's Disease Neuroimaging Initiative, 2017. Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.
• Ng, K.P., Ng, A., Assam, P., Heng, E. and Kandiah, N., 2014. Role of cognitive enhancer therapy in Alzheimer’s disease with concomitant cerebral white matter disease: findings from a long-term naturalistic study. Drugs in R&d, 14(3), pp.195-203.
• Ba, M., Li, X., Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Rosa-Neto, P., Gauthier, S. and Alzheimer's Disease Neuroimaging Initiative, 2017. The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 3(1), pp.107-113.
• Ba, M., Kong, M., Li, X., Ng, K.P., Rosa-Neto, P. and Gauthier, S., 2016. Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?. Translational Neurodegeneration, 5(1), p.20.